Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia
Authors
Keywords
-
Journal
Stem Cells Translational Medicine
Volume 11, Issue 4, Pages 407-414
Publisher
Oxford University Press (OUP)
Online
2022-02-18
DOI
10.1093/stcltm/szac007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
- (2021) Sherif M. Badawy et al. Blood Advances
- β-Thalassemias
- (2021) Ali T. Taher et al. NEW ENGLAND JOURNAL OF MEDICINE
- A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease
- (2021) Alexis Leonard et al. MOLECULAR THERAPY
- Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen
- (2020) Usanarat Anurathapan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation
- (2020) Dimitrios Farmakis et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
- (2020) M. Domenica Cappellini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease
- (2020) Matthew M. Hsieh et al. Blood Advances
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
- (2020) Haydar Frangoul et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia
- (2019) Sarah Marktel et al. NATURE MEDICINE
- Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation
- (2019) Séverine Coquerelle et al. HUMAN GENE THERAPY
- Gene therapy of hemoglobinopathies: progress and future challenges
- (2019) Yasuhiro Ikawa et al. HUMAN MOLECULAR GENETICS
- Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study
- (2019) Mary Eapen et al. Lancet Haematology
- Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia
- (2019) Angela R. Smith et al. BLOOD
- Benefit Corporation: a path to affordable gene therapies?
- (2019) Alain Fischer et al. NATURE MEDICINE
- Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
- (2018) Alexis A. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene therapy: evidence, value and affordability in the US health care system
- (2018) Grace Hampson et al. Journal of Comparative Effectiveness Research
- Health-related quality of life (HRQoL) in beta-thalassemia major (β-TM) patients assessed by 36-item short form health survey (SF-36): a meta-analysis
- (2018) Mahdieh Arian et al. QUALITY OF LIFE RESEARCH
- The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
- (2017) Robert Hettle et al. HEALTH TECHNOLOGY ASSESSMENT
- Gene Therapy Approaches to Hemoglobinopathies
- (2017) Giuliana Ferrari et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010
- (2016) D Baronciani et al. BONE MARROW TRANSPLANTATION
- Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects
- (2016) Jorge Mansilla-Soto et al. HUMAN GENE THERAPY
- Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom
- (2016) Diana Weidlich et al. TRANSFUSION
- BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
- (2015) Matthew C. Canver et al. NATURE
- Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
- (2014) E. Angelucci et al. HAEMATOLOGICA
- Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia
- (2013) G. La Nasa et al. BLOOD
- Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling
- (2013) F. Locatelli et al. BLOOD
- Hematopoietic Stem Cell Mobilization for Gene Therapy: Superior Mobilization by the Combination of Granulocyte–Colony Stimulating Factor Plus Plerixafor in Patients with β-Thalassemia Major
- (2013) Evangelia Yannaki et al. HUMAN GENE THERAPY
- Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease
- (2011) Annalisa Ruggeri et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population
- (2011) Vassilis Ladis et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Distribution of Lentiviral Vector Integration Sites in Mice Following Therapeutic Gene Transfer to Treat β-thalassemia
- (2011) Keshet Ronen et al. MOLECULAR THERAPY
- Quality of life in thalassemia: A comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms
- (2010) A. Sobota et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation
- (2010) Giovanni Caocci et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- What is the minimum level of donor chimerism necessary to sustain transfusion independence in thalassaemia?
- (2010) A Alfred et al. BONE MARROW TRANSPLANTATION
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
- (2010) Marina Cavazzana-Calvo et al. NATURE
- The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy
- (2009) Eugenio Montini et al. JOURNAL OF CLINICAL INVESTIGATION
- Genotoxic Potential of Lineage-specific Lentivirus Vectors Carrying the β-Globin Locus Control Region
- (2009) Paritha I Arumugam et al. MOLECULAR THERAPY
- Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors
- (2008) Daniela Zychlinski et al. MOLECULAR THERAPY
- Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific RepressorBCL11A
- (2008) Vijay G. Sankaran et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now